CCRM Nordic Announces Transfer of CombiGene AB’s Minority Stake Amid Ongoing Strategic Restructuring

CCRM Nordic today announced that CombiGene AB has transferred its minority ownership stake in CCRM Nordic as part of CombiGene’s ongoing strategic restructuring. In accordance with the shareholder agreement, CombiGene’s shares have been transferred to GU Ventures for an interim period until a third party acquires the shares. CombiGene has been a valued partner and member of the industry consortia; however, their departure does not affect CCRM Nordic’s ongoing operations, which will continue as planned and in accordance with our strategic objectives.

CombiGene’s departure from CCRM is a consequence of its decision to withdraw from all research-related activities. Further information on CombiGene’s restructuring can be found at https://combigene.com.

Contacts 

Fredrik Wessberg, fredrik.wessberg@ccrmnordic.se 

About CCRM Nordic: 

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs. 

About CCRM: 

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca